This technology features a pharmaceutical composition for the prevention and treatment of sarcopenia, and a food composition for prevention and improvement, containing caryophyllene oxide—a phytoncide component—as an active ingredient along with cedrol. Both components inhibit the expression of myostatin, which causes muscle loss.
Sarcopenia is a condition characterized by the age-related loss of skeletal muscle mass and strength, with prevalence rising rapidly alongside the aging population. Exercise is difficult to maintain as a long-term treatment, while testosterone and anabolic steroids carry side effects such as masculinization in women or prostate issues in men. Dietary approaches also have limitations in maintaining sufficient muscle mass.
This technology is designed to lower the expression of not only myostatin, which inhibits muscle growth, but also MURF1 and Foxo3, which are involved in muscle protein degradation, making it effective even in cases of muscle loss induced by bleomycin or UV exposure. It can be applied to treatments for geriatric sarcopenia, muscle loss management for cancer patients, and health supplements for muscle maintenance using forest-derived ingredients, offering a more fundamental approach to inhibiting muscle loss by directly targeting myostatin, the upstream signal for muscle reduction.
WO2020-017915A1
